A Phase Ib Open-Label Two Arm Study of Pembrolizumab for Unresectable or Metastatic Basal Cell Carcinoma

Trial Profile

A Phase Ib Open-Label Two Arm Study of Pembrolizumab for Unresectable or Metastatic Basal Cell Carcinoma

Recruiting
Phase of Trial: Phase I

Latest Information Update: 28 Jun 2017

At a glance

  • Drugs Pembrolizumab (Primary) ; Vismodegib (Primary)
  • Indications Basal cell cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 06 Jun 2017 According to trial design presented at the 53rd Annual Meeting of the American Society of Clinical Oncology, ten patients out of twenty-six (6 in arm 1 and 4 in arm 2) have been enrolled.
    • 06 Jun 2017 Trial design presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 06 Jun 2017 Planned number of patients changed from 24 to 26, according to trial design presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top